Meet with our clients in San Francisco! #JPM2025
This content isn’t available here
Access this content and more in the LinkedIn app
Precision AQ - Investor Relations & External Communications is a premier investor relations firm, representing biotechnology companies across all market capitalizations and stages of development, and offering strategic and client-specific advisory services. For more information please visit our website at www.precisionaq.com
External link for Precision AQ - Investor Relations & External Communications
1270 Avenue of the Americas
New York, 10020, US
Meet with our clients in San Francisco! #JPM2025
This content isn’t available here
Access this content and more in the LinkedIn app
Join us in San Francisco for our 19th Annual Corporate Access Event, happening January 13th-16th at The Marker Hotel! We are excited to provide a platform for meaningful discussions with biotech innovators and industry leaders. This is your chance to connect with trailblazers shaping the future of healthcare and scientific discovery. Don't miss your chance to schedule one-on-one meetings with our clients. Set up your meetings now by visiting: https://lnkd.in/gEsWCVhj #JPM2025 #CorporateAccess #biotech #sanfrancisco #investorrelations #innovation
Precision AQ - Investor Relations & External Communications reposted this
Did you know gratitude benefits for your overall wellbeing? It strengthens our feelings of connection, alleviates depression, and increases our sense of engagement with the world around us. As we reflect on what we are thankful for, we wish our friends, family, and colleagues a holiday season brimming with gratitude. We especially want to express our appreciation to our employees and clients for their boundless enthusiasm and tireless commitment to advancing the medical treatments that improve the quality of life for patients in need.
We are very excited that our own Stephanie Ascher will be joining other industry experts tomorrow for a webinar about mastering AI in IR! Thanks for having us IR Magazine and Q4. Register and join us tomorrow using the following link: https://lnkd.in/e62x8prK
We're thrilled to have leading experts joining us on tomorrow's webinar all about mastering AI in IR while keeping your data safe and secure! We'll be hearing from: ▫️ Mark Hayes, partner and head of capital markets at Breakwater Strategy ▫️ Simone P., principal product manager at Q4 ▫️ Stephanie Ascher, managing director and team lead at Precision AQ ▫️ Moderator: Laurie Havelock, editor of IR Magazine It's free to attend and will get you up to speed in just 45 minutes. Register online at https://lnkd.in/e62x8prK In partnership with Q4
Precision AQ - Investor Relations & External Communications reposted this
Be part of a group that has supported a growing number of “firsts” in breakthrough treatments for patients. Precision AQ is part of Precision Medicine Group along with Precision For Medicine. Together our expertise and capabilities span the continuum of pre-clinical and clinical development through commercialization. A few of the “firsts” we’ve supported on behalf of our clients include: 1st PD-1 inhibitor approved to treat cancer 1st CAR-T cell therapy ever approved by the FDA 1st CRISPR-based genome editing therapy ever approved by the FDA 1st ever commercial gene therapy for children with SMA And many more… See our story in the new video and consider joining us! We are hiring around the world. Find your position at https://lnkd.in/er6dWy3W
Congratulations to client LENZ Therapeutics on the announcement of their FDA NDA acceptance. The FDA has set their PDUFA date for August 2025!
{{linkedin_mention(urn:li:organization:78005945|LENZ Therapeutics)}} Announces FDA Acceptance of New Drug Application for LNZ100 for the Treatment of Presbyopia. FDA sets Prescription Drug User Fee Act (PDUFA) target date of August 8, 2025 “With the acceptance of our New Drug Application for LNZ100, we are pleased to be one step closer towards potential approval and look forward to continuing to collaborate with the FDA to deliver the first once-daily, well-tolerated and rapid acting eye drop for the treatment of presbyopia to the 128 million individuals living with blurry near vision in the United States,” said {{linkedin_mention(urn:li:person:T3JA8UK24G|Eef Schimmelpennink)}}, President and Chief Executive Officer of LENZ Therapeutics. “Since our public debut in March 2024, we have generated tremendous momentum and demonstrated consistent clinical, regulatory and financial execution, and are focused on transforming LENZ into a robust commercial organization in anticipation of a potential launch as early as the second half of 2025.” Read full press release here: https://lnkd.in/gKz5jKfy
Congratulations to client Avadel Pharmaceuticals PLC on the announcement of FDA approval of #LUMRYZ for the treatment of cataplexy or excessive daytime sleepiness in patients 7 years of age and older with #narcolepsy!
We’re pleased to announce an important milestone for the #narcolepsy community, specifically for pediatric patients and their caregivers. Learn more about another positive step in our efforts to transform the lives of people with narcolepsy. https://lnkd.in/gFm6kxvx
✨ Last chance! ✨ We have a few spots left to join our virtual event TODAY at 12pm ET. Discover how Precision AQ can simplify your experience around #JPMorgan2025! Click here to register: https://lnkd.in/dSUQgrBP
Join our virtual event this Thursday, October 17th at 12pm ET to discover how Precision AQ can simplify your experience around #JPMorgan2025. This is your opportunity to partner with a team that makes your conference experience effortless and empowers you to focus on driving your life-changing innovations forward. Click here to register: https://lnkd.in/dSUQgrBP
The JP Morgan Healthcare Conference transforms San Francisco into the epicenter of #biotech: every year, industry giants unveil big news and early-stage companies strive to make their mark. As you prepare your data, slides, and talking points, there’s a crucial element you can’t overlook—logistics. Join our virtual event on Thursday, October 17th at 12pm ET to discover how Precision AQ can simplify your experience around #JPMorgan2025. This is your opportunity to partner with a team that makes your conference experience effortless and empowers you to focus on driving your life-changing innovations forward. Click here to register: https://lnkd.in/dSUQgrBP